News

Kaken Pharmaceutical has secured the rights to develop and commercialize navenibart, an investigational treatment for hereditary angioedema (HAE), in Japan. Kaken will pay $16 million as part of an agreement with navenibart developer Astria Therapeutics that includes another $16 million if development and sales milestones are…

Delays in administering on-demand treatment are common in hereditary angioedema (HAE), with 51% of patients receiving treatment more than two hours after the onset of an attack, according to a survey in Italy that found that delaying treatment correlates with greater attack severity. The findings underscore the need to…

Haloperidol, an antipsychotic medication commonly used to treat schizophrenia and severe agitation, was behind a rare case of angioedema of the tongue — a sudden, potentially life-threatening swelling — for a man in Tunisia, as detailed a case report. Although angioedema can occur as an allergic reaction or as…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended that sebetralstat be approved as an on-demand treatment for acute attacks in people with hereditary angioedema (HAE), ages 12 and older. “This positive CHMP opinion is an important step forward for people living…

People with hereditary angioedema (HAE) types 1 and 2 had fewer swelling attacks and reported improvements in quality of life after they switched to donidalorsen from other preventive therapies, according to interim data from an ongoing clinical trial. “The study was designed to provide patients and physicians with…

A woman was diagnosed with hereditary angioedema (HAE) 20 years after her first symptoms, according to a case report in Nepal. The case highlights “the importance of early diagnosis and effective management to alleviate patient suffering,” the report’s researchers wrote. The case report, “A Two-Decade-Delayed Diagnosis…

Ekterly (sebetralstat) has been approved in the U.K. for treating swelling attacks on demand in people with hereditary angioedema (HAE), ages 12 and older, according to its developer, Kalvista Pharmaceuticals. This makes the therapy the first and only oral on-demand HAE therapy approved in the U.K. It…

Pharvaris expects to ask the U.S. Food and Drug Administration to approve deucrictibant as an on-demand treatment for hereditary angioedema (HAE) attacks next year. The application will cover the immediate-release (IR) capsule formulation of the therapy, which is intended to control swelling attacks as they occur. The submission…

People with type 2 diabetes who use DPP4 inhibitors to manage their disease do not seem to have a higher risk of developing angioedema compared with those taking other oral antidiabetic medications. That’s according to a study in South Korea, which found that new cases of angioedema occurred at…

The U.S. Food and Drug Administration (FDA) has approved sebetralstat for the on-demand treatment of swelling attacks in adults and children, ages 12 and older, with hereditary angioedema (HAE), its developer Kalvista Pharmaceuticals announced. Sebetralstat will be sold under the brand name Ekterly, and is the first…